The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Kenneth S. Cohen and Theodore Karrison.
Connection Strength

0.255
  1. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
    View in: PubMed
    Score: 0.155
  2. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
    View in: PubMed
    Score: 0.056
  3. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.